Interestingly, when correcting for age and sex as well as the medications taken using a multiple linear regression, the administration of monoamine oxidase type B (MAO-B) inhibitors was associated with significantly higher wetting lengths in the PD group (17.5 ± 10.6 mm/10 min for MAO-B inhibitor taking patients, 9.9 ± 7.2 mm/10 min for non-MAO-B inhibitor taking patients, p = 0.001, estimate = 8.69 [3.61, 13.77]). This evidence concerns the gene MAOB and Parkinson disease.